Last Price
15.80
Today's Change
-0.15 (0.94%)
Day's Change
15.41 - 16.00
Trading Volume
49,741
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Riad Sherif M.B.A., M.D. Dr. Riad Sherif M.B.A., M.D.
Full Time Employees: 36 36
IPO Date: 2021-05-18 2021-05-18
CIK: 0001953530 0001953530
ISIN: CH1242303498 CH1242303498
Beta: 0.09 0.09
Last Dividend: 0.00 0.00
Dcf Diff: 15.46 15.46
Dcf: 0.34 0.34
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.